陈家齐：港投公司去年投资收益逾20亿港元 已投放资金不足20%

Core Viewpoint - The Hong Kong investment company has reported its investment performance for the first time since its establishment three years ago, highlighting significant returns from investments in IPOs and biotech firms, projecting over HKD 2 billion in investment gains for 2024 [1] Group 1: Investment Performance - The investment company was founded in 2022 with an initial investment fund of HKD 62 billion, but less than 20% of this capital has been deployed as of the end of last year [1] - The company has also secured approximately HKD 2.8 billion from new capital investors [1] - The CEO stated that the investment speed and returns are fully aligned with the set goals, emphasizing the need to balance investment risks with speed [1] Group 2: Future Investment Strategy - The investment fund has entered its second phase, seeking partnerships with sovereign wealth funds, retirement funds, and corporations for larger-scale investments [1] - There is significant interest from Southeast Asian and Middle Eastern investors in investing in Hong Kong and mainland enterprises [1] - The company plans to systematically increase its investment efforts over the next year, focusing on four major portfolios that cover technology and biotech sectors, involving a total of 150 companies [1] Group 3: Growth Drivers - The growth of the investment fund is expected to be primarily driven by biotech companies, with many within the fund exploring possibilities for IPOs or mergers [1] - Two companies that have already gone public in Hong Kong have generated returns of two to three times for the fund [1]